IL1B and atrial fibrillation: More important, we show that neutralizing circulating IL-1β by treating mice with anti–IL-1β antibody could reduce the susceptibility to CKD-induced AF, providing a proof of concept for targeting IL-1β in patients with CKD who are at risk for AF.